Literature DB >> 18156802

Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts.

Pablo Perez-Pinera1, Yunchao Chang, Thomas F Deuel.   

Abstract

Pleiotrophin (PTN, Ptn) is a widely expressed, developmentally regulated 136 amino acid secreted heparin-binding cytokine. It signals through a unique signaling pathway; the PTN receptor is the transmembrane receptor protein tyrosine phosphatase (RPTP)beta/zeta. RPTPbeta/zeta is inactivated by PTN, which leads to increased tyrosine phosphorylation of the downstream targets of the PTN/RPTPbeta/zeta signaling pathway. Pleiotrophin gene expression is found in cells in early differentiation during different developmental periods. It is upregulated in cells with an early differentiation phenotype in wound repair. The Ptn gene also is a proto-oncogene; PTN is expressed in human tumor cells, and, in cell lines derived from human tumors that express Ptn, Ptn expression is constitutive and thus "inappropriate". Importantly, properties of different cells induced by PTN in PTN-stimulated cells are strikingly similar to properties of highly malignant cells. Furthermore, transformed cells into which Ptn is introduced undergo "switches" to malignant cells of higher malignancy with properties that are strikingly similar to properties of PTN-stimulated cells. These unique features of PTN support the conclusion that constitutive PTN signaling in malignant cells that inappropriately express Ptn functions as a potent tumor promoter. Recently, in confirmation, Ptn targeted by the mouse mammary tumor virus (MMTV) promoter in a transgenic mouse model was found to promote breast cancers to a more aggressive breast cancer cell phenotype that morphologically closely resembles scirrhous carcinoma in human; in addition, it promoted a striking increase in tumor angiogenesis and a remarkable degree of remodeling of the micro-environment. Pleiotrophin thus regulates both different normal and pathological functions; collectively, the different studies have uncovered the unique ability of a single cytokine PTN, which signals through the unique PTN/RPTPbeta/zeta signaling pathway, to induce the many properties associated with tumor promotion in the malignant cells that constitutively express Ptn and in their microenvironment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18156802     DOI: 10.4161/cc.6.23.5090

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  31 in total

1.  Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling.

Authors:  Heather A Himburg; Martina Roos; Tiancheng Fang; Yurun Zhang; Christina M Termini; Lauren Schlussel; Mindy Kim; Amara Pang; Jenny Kan; Liman Zhao; Hyung Suh; Joshua P Sasine; Gopal Sapparapu; Peter M Bowers; Gary Schiller; John P Chute
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Menin represses tumorigenesis via repressing cell proliferation.

Authors:  Ting Wu; Xianxin Hua
Journal:  Am J Cancer Res       Date:  2011-05-16       Impact factor: 6.166

3.  Estrogen Stimulation of Pleiotrophin Enhances Osteoblast Differentiation and Maintains Bone Mass in IGFBP-2 Null Mice.

Authors:  Gang Xi; Victoria E Demambro; Susan D'Costa; Shalier K Xia; Zach C Cox; Clifford J Rosen; David R Clemmons
Journal:  Endocrinology       Date:  2020-04-01       Impact factor: 4.736

Review 4.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Structural studies reveal an important role for the pleiotrophin C-terminus in mediating interactions with chondroitin sulfate.

Authors:  Eathen Ryan; Di Shen; Xu Wang
Journal:  FEBS J       Date:  2016-03-06       Impact factor: 5.542

6.  The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity.

Authors:  Peter Landgraf; Petra Wahle; Hans-Christian Pape; Eckart D Gundelfinger; Michael R Kreutz
Journal:  J Biol Chem       Date:  2008-07-03       Impact factor: 5.157

7.  Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

Authors:  Stephen G Chun; Kevin S Choe; Puneeth Iyengar; John S Yordy; Robert D Timmerman
Journal:  Cancer Biol Ther       Date:  2012-09-17       Impact factor: 4.742

8.  PAX3-FKHR regulates the expression of pleiotrophin to mediate motility in alveolar rhabdomyosarcoma cells.

Authors:  Lingling Liu; Taosheng Chen
Journal:  J Can Res Updates       Date:  2012-01-01

9.  CCL5 secreted by senescent aged fibroblasts induces proliferation of prostate epithelial cells and expression of genes that modulate angiogenesis.

Authors:  D Eyman; M Damodarasamy; S R Plymate; M J Reed
Journal:  J Cell Physiol       Date:  2009-08       Impact factor: 6.384

10.  Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate.

Authors:  Howard Kendrick; Joseph L Regan; Fiona-Ann Magnay; Anita Grigoriadis; Costas Mitsopoulos; Marketa Zvelebil; Matthew J Smalley
Journal:  BMC Genomics       Date:  2008-12-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.